
ML239
CAS No. 1378872-36-6
ML239( —— )
Catalog No. M17266 CAS No. 1378872-36-6
ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 39 | In Stock |
![]() ![]() |
10MG | 65 | In Stock |
![]() ![]() |
25MG | 129 | In Stock |
![]() ![]() |
50MG | 250 | In Stock |
![]() ![]() |
100MG | 429 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameML239
-
NoteResearch use only, not for human use.
-
Brief DescriptionML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
-
DescriptionML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
-
In VitroML239 (Compound 7j) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM, with ~24-fold selectivity against the control cell line. ML239 inhibits breast cancer stem-like cells, most likely through activation of fatty acid desaturase 2 (FADS2). ML239 is cytotoxic to NCIH661 cells, and FADS2 knockdown reduces ML239 cytotoxicity, and furthermore, FADS2 inhibitor SC-26196 also reduces ML239 cytotoxicity in cancer cell lines (CCLs).
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptorOthers
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1378872-36-6
-
Formula Weight346.59
-
Molecular FormulaC13H10Cl3N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 300 mg/mL 865.55 mM
-
SMILESClc2cc(Cl)cc(Cl)c2OCC(=O)N\N=C\c1cccn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Germain AR,etal.Identification of a selective small molecule inhibitor of breast cancer stem cells.Bioorg Med Chem Lett. 2012 May 15;22(10):3571-4.
molnova catalog



related products
-
PRT-060318
PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.
-
Sapanisertib
Sapanisertib (INK-128, MLN0128) is a potent, ATP-competitive, orally active dual mTORC1/2 inhibitor with Ki of 1.4 nM in cell-free assays.
-
Autogramin-1
Autogramin-1 potently inhibits starvation-induced autophagy with IC50 of 0.17 μM.